Abivax Aligns with FDA on Obefazimod NDA Submission
PARIS, France, July 30, 2026 Abivax SA announced the successful completion of a positive pre-New Drug Application (pre-NDA) interaction...
NDA
Advertisement
Medicus Pharma Receives FDA Clearance for Registrational SkinJect Study
PHILADELPHIA, July 27, 2026 Medicus Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has issued a...
LB Pharmaceuticals Accelerates Phase 3 LB-102 Schizophrenia Timeline
New York, July 22, 2026 LB Pharmaceuticals announced that it now expects to report topline results from the pivotal...
Revolution Medicines FDA Accepts Daraxonrasib NDA for Pancreatic Cancer
Revolution Medicines, Redwood City, Calif., July 22, 2026 Revolution Medicines announced that the U.S. Food and Drug Administration (FDA)...
Belite Bio Reports Positive Phase 3 Tinlarebant Data at ASRS 2026
SAN DIEGO, July 20, 2026 Belite Bio, Inc. (NASDAQ: BLTE) announced additional positive secondary endpoint data from its Phase...
Advertisements
Camurus NDA Resubmission for CAM2029 Accepted by FDA
LUND, Sweden, July 17, 2026 Camurus announced that the U.S. Food and Drug Administration (FDA) has accepted for review...
Praxis and Remagine Collaborate on Ulixacaltamide
BOSTON, Mass. and AUSTIN, Texas, July 7, 2026 Praxis Precision Medicines and Remagine Labs have entered into a strategic...
Apnimed Appoints Industry Veterans to Drive AD109 Growth
CAMBRIDGE, Mass., July 1, 2026 Apnimed has strengthened its executive leadership team with the appointments of Michael Kelly as...
Abivax Reports Positive Phase 3 Obefazimod Maintenance Data
PARIS, France, June 29, 2026 Abivax SA announced positive topline results from ABTECT Maintenance Part 2, the supplemental portion...
Praxis Precision Medicines Extends FDA Review for Relutrigine NDA
BOSTON, June 29, 2026 Praxis Precision Medicines announced that the U.S. Food and Drug Administration (FDA) has extended the...
Advertisement
